Calamos Advisors LLC Purchases 20,071 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Calamos Advisors LLC increased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 33.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,266 shares of the medical research company's stock after purchasing an additional 20,071 shares during the quarter. Calamos Advisors LLC's holdings in IQVIA were worth $13,975,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also bought and sold shares of IQV. Norges Bank bought a new stake in shares of IQVIA in the 4th quarter worth approximately $336,041,000. Raymond James Financial Inc. bought a new stake in shares of IQVIA in the 4th quarter worth approximately $236,120,000. American Century Companies Inc. boosted its position in shares of IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after purchasing an additional 905,960 shares in the last quarter. Invesco Ltd. boosted its position in shares of IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after purchasing an additional 902,226 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in shares of IQVIA by 20.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after purchasing an additional 712,958 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $0.41 during midday trading on Friday, hitting $164.24. The company had a trading volume of 674,106 shares, compared to its average volume of 1,653,324. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. The company has a market cap of $28.41 billion, a price-to-earnings ratio of 22.38, a PEG ratio of 1.82 and a beta of 1.30. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a fifty day moving average of $150.86 and a two-hundred day moving average of $173.16.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. IQVIA's revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.54 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on IQV shares. Redburn Partners set a $188.00 price target on IQVIA in a research report on Friday, May 23rd. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. UBS Group decreased their price objective on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Truist Financial decreased their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a report on Thursday, April 10th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $226.32.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.